Program
Carbon-14
Also written as “Carbon-14 BIA 28-6156”, “Carbon-14 labeled HSK39297” and “carbon-14-[14C]-ANG-3777”.
Its studies are mostly in Parkinson Disease · Hemoglobinuria, Paroxysmal · Diabetes Mellitus, Type 2, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Angion Biomedica | 10 open or running | phase 1since May 28, 2021 | May 28, 2021 | none ahead |
| Bial - Portela C | 10 open or running | phase 1since Nov 18, 2021 | Nov 18, 2021 | none ahead |
| GlaxoSmithKline | 10 open or running | phase 1since Jul 9, 2009 | Jul 9, 2009 | none ahead |
| Haisco Pharmaceutical Group | 10 open or running | phase 1since Feb 24, 2025 | Feb 24, 2025 | none ahead |
Also a collaborator on its studies: quotient-sciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 9, 2009First study: phase 1 study in Diabetes Mellitus, Type 2New to GlaxoSmithKlineGlaxoSmithKline · NCT00937872 · 9 enrolled · United Kingdom
- May 28, 2021Angion Biomedica's first study: phase 1 study in HealthyNew to Angion BiomedicaAngion Biomedica · NCT04931524 · 6 enrolled · United Kingdom
- Nov 18, 2021Bial - Portela C's first study: phase 1 study in Parkinson DiseaseNew to Bial - Portela CBial - Portela C · NCT05220072 · 6 enrolled · United Kingdom
- Feb 24, 2025Haisco Pharmaceutical Group's first study: phase 1 study in Hemoglobinuria, ParoxysmalNew to Haisco Pharmaceutical GroupHaisco Pharmaceutical Group · NCT06852092 · 7 enrolled · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06852092Hemoglobinuria, Paroxysmal · China | 1 | Completed | Haisco Pharmaceutical Group | Sep 27, 2024 | 7 |
| NCT05220072Parkinson Disease · United Kingdom | 1 | Completed | Bial - Portela C | Oct 16, 2021 | 6 |
| NCT04931524Healthy · United Kingdom | 1 | UNKNOWN | Angion Biomedica | Jun 2021 | 6 |
| NCT00937872Diabetes Mellitus, Type 2 · United Kingdom | 1 | Completed | GlaxoSmithKline | Dec 22, 2008 | 9 |
How it is read
Names in the registry
- “Carbon-14 BIA 28-6156”, 1 entry
- “Carbon-14 labeled HSK39297”, 1 entry
- “carbon-14-[14C]-ANG-3777”, 1 entry
- “Carbon-14 radio-labeled SRT2104”, 1 entry
Conditions, from the studies’ own filings
- Parkinson Disease, 1 study
- Hemoglobinuria, Paroxysmal, 1 study
- Diabetes Mellitus, Type 2, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.